WAT - CIK 0001000697
WATERS CORP /DE/ trades as WAT and has a market capitalization of $35.66 B, making it the #415 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $3.17B, up 7.0% from the prior year and net income of $642.63M. This page tracks WATERS CORP /DE/ through 1,887 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years WATERS CORP /DE/'s revenue grew from $2.17B to $3.17B, a compound annual growth rate of 4.3%. Net profit margin compressed from 24.9% to 20.3% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| Insider trade | 4 | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-12 |
| Major company event | 8-K | 2026-05-05 |
| SCHEDULE 13G | - | 2026-04-30 |
| SCHEDULE 13G/A | - | 2026-04-24 |
| Annual report to shareholders | ARS | 2026-04-09 |
| Proxy materials | DEFA14A | 2026-04-09 |
A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will be available for 90 days.
_Total reported revenue of $1.267 billion exceeded the high end of the guidance range by $56 million, driven by strong outperformance in both organic revenue and the acquired businesses._
Waters Corporation (NYSE: WAT) is a global leader in life sciences and diagnostics, dedicated to accelerating the benefits of pioneering science through analytical technologies, informatics, and service. With a focus on regulated, high-volume testing environments, our innovative portfolio harnesses deep scientific expertise across chemistry, physics, and biology. We collaborate with customers around the world to advance the release of effective, high-quality medicines, ensure the safety of food and water, and drive better patient outcomes by detecting diseases earlier, managing routine infections, and combating antibiotic resistance. Through a shared culture of relentless innovation, our passionate team of ~16,000 colleagues turn scientific challenges into breakthroughs that improve lives worldwide. For more information, please visit www.waters.com/about.
The largest companies sharing WATERS CORP /DE/'s SEC industry classification (laboratory analytical instruments).
WATERS CORP /DE/ (WAT) has a market capitalization of $35.66 B as of 2026-06-10, ranking #415 among US-listed companies.
WATERS CORP /DE/ reported revenue of $3.17B for fiscal year 2025, an increase of 7.0% year over year.
Yes. WATERS CORP /DE/ reported net income of $642.63M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
Delivers up to 4x faster chromatographic run times to accelerate decisions across discovery, development, and quality workflows.1,3
FDA-approved BD Onclarity™ HPV Assay is the most comprehensive screening tool for HPV in the U.S.1,4 with extended genotyping and end-to-end automated lab workflows.